DK2949335T3 - Lavfrekvent glatiramer-acetat-terapi - Google Patents
Lavfrekvent glatiramer-acetat-terapi Download PDFInfo
- Publication number
- DK2949335T3 DK2949335T3 DK15171065.4T DK15171065T DK2949335T3 DK 2949335 T3 DK2949335 T3 DK 2949335T3 DK 15171065 T DK15171065 T DK 15171065T DK 2949335 T3 DK2949335 T3 DK 2949335T3
- Authority
- DK
- Denmark
- Prior art keywords
- multiple sclerosis
- glatiramer acetate
- treatment
- injection
- patient
- Prior art date
Links
- 108010072051 Glatiramer Acetate Proteins 0.000 title claims description 158
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 title claims description 151
- 229960003776 glatiramer acetate Drugs 0.000 title claims description 151
- 238000002560 therapeutic procedure Methods 0.000 title description 6
- 238000011282 treatment Methods 0.000 claims description 81
- 201000006417 multiple sclerosis Diseases 0.000 claims description 68
- 238000010254 subcutaneous injection Methods 0.000 claims description 55
- 239000007929 subcutaneous injection Substances 0.000 claims description 53
- 239000003814 drug Substances 0.000 claims description 37
- 230000001965 increasing effect Effects 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 206010022095 Injection Site reaction Diseases 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 12
- 206010067142 Immediate post-injection reaction Diseases 0.000 claims description 11
- 229930195725 Mannitol Natural products 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- 239000000594 mannitol Substances 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 206010048393 Multiple sclerosis relapse Diseases 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 description 66
- 230000003902 lesion Effects 0.000 description 56
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 44
- 230000003442 weekly effect Effects 0.000 description 44
- 208000024891 symptom Diseases 0.000 description 41
- 238000000034 method Methods 0.000 description 38
- 239000000902 placebo Substances 0.000 description 38
- 229940068196 placebo Drugs 0.000 description 38
- 238000002347 injection Methods 0.000 description 24
- 239000007924 injection Substances 0.000 description 24
- 238000012216 screening Methods 0.000 description 21
- 238000002595 magnetic resonance imaging Methods 0.000 description 20
- 230000008859 change Effects 0.000 description 16
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 description 14
- 208000002193 Pain Diseases 0.000 description 11
- 230000036407 pain Effects 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 208000024806 Brain atrophy Diseases 0.000 description 9
- 230000001186 cumulative effect Effects 0.000 description 8
- 230000002708 enhancing effect Effects 0.000 description 8
- 206010015150 Erythema Diseases 0.000 description 7
- 230000009266 disease activity Effects 0.000 description 7
- 231100000321 erythema Toxicity 0.000 description 7
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 206010013975 Dyspnoeas Diseases 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 208000003251 Pruritus Diseases 0.000 description 6
- 208000001871 Tachycardia Diseases 0.000 description 6
- 208000024780 Urticaria Diseases 0.000 description 6
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 6
- 230000006735 deficit Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 208000035824 paresthesia Diseases 0.000 description 6
- 229940071643 prefilled syringe Drugs 0.000 description 6
- 230000006794 tachycardia Effects 0.000 description 6
- 206010067063 Progressive relapsing multiple sclerosis Diseases 0.000 description 5
- 206010044565 Tremor Diseases 0.000 description 5
- 208000012886 Vertigo Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 229940038717 copaxone Drugs 0.000 description 5
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 5
- 231100000889 vertigo Toxicity 0.000 description 5
- 206010003591 Ataxia Diseases 0.000 description 4
- 206010071068 Clinically isolated syndrome Diseases 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 206010072731 White matter lesion Diseases 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- 206010001497 Agitation Diseases 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 208000008035 Back Pain Diseases 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 206010008479 Chest Pain Diseases 0.000 description 3
- 206010008469 Chest discomfort Diseases 0.000 description 3
- 206010011732 Cyst Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010014020 Ear pain Diseases 0.000 description 3
- 206010014080 Ecchymosis Diseases 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 3
- 206010016029 Face oedema Diseases 0.000 description 3
- 206010016334 Feeling hot Diseases 0.000 description 3
- 208000005577 Gastroenteritis Diseases 0.000 description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 208000009889 Herpes Simplex Diseases 0.000 description 3
- 206010060800 Hot flush Diseases 0.000 description 3
- 208000008454 Hyperhidrosis Diseases 0.000 description 3
- 206010020852 Hypertonia Diseases 0.000 description 3
- 206010060708 Induration Diseases 0.000 description 3
- 206010022061 Injection site erythema Diseases 0.000 description 3
- 206010022067 Injection site haemorrhage Diseases 0.000 description 3
- 206010022075 Injection site induration Diseases 0.000 description 3
- 206010022078 Injection site inflammation Diseases 0.000 description 3
- 206010022081 Injection site mass Diseases 0.000 description 3
- 206010022086 Injection site pain Diseases 0.000 description 3
- 206010022093 Injection site pruritus Diseases 0.000 description 3
- 206010022107 Injection site urticaria Diseases 0.000 description 3
- 208000009612 Laryngismus Diseases 0.000 description 3
- 206010023891 Laryngospasm Diseases 0.000 description 3
- 206010027566 Micturition urgency Diseases 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 206010028836 Neck pain Diseases 0.000 description 3
- 206010029216 Nervousness Diseases 0.000 description 3
- 206010030124 Oedema peripheral Diseases 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 206010034701 Peroneal nerve palsy Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 206010067868 Skin mass Diseases 0.000 description 3
- 206010047141 Vasodilatation Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 206010003549 asthenia Diseases 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 208000031513 cyst Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 208000010643 digestive system disease Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000005713 exacerbation Effects 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 208000030533 eye disease Diseases 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 208000018685 gastrointestinal system disease Diseases 0.000 description 3
- 210000004884 grey matter Anatomy 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 230000007971 neurological deficit Effects 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 238000010984 neurological examination Methods 0.000 description 3
- 206010029864 nystagmus Diseases 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 206010039083 rhinitis Diseases 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 208000027765 speech disease Diseases 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 230000035900 sweating Effects 0.000 description 3
- 206010042772 syncope Diseases 0.000 description 3
- 230000024883 vasodilation Effects 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 210000004885 white matter Anatomy 0.000 description 3
- YLOCGHYTXIINAI-XKUOMLDTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YLOCGHYTXIINAI-XKUOMLDTSA-N 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 206010006784 Burning sensation Diseases 0.000 description 2
- 206010009696 Clumsiness Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010010947 Coordination abnormal Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- 208000019505 Deglutition disease Diseases 0.000 description 2
- 208000003164 Diplopia Diseases 0.000 description 2
- 206010016059 Facial pain Diseases 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010021639 Incontinence Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000003435 Optic Neuritis Diseases 0.000 description 2
- 206010040030 Sensory loss Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- 159000000021 acetate salts Chemical class 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000037007 arousal Effects 0.000 description 2
- 230000007844 axonal damage Effects 0.000 description 2
- 230000003376 axonal effect Effects 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000003210 demyelinating effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 229940042385 glatiramer Drugs 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 208000028756 lack of coordination Diseases 0.000 description 2
- 208000018883 loss of balance Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000013465 muscle pain Diseases 0.000 description 2
- 210000003007 myelin sheath Anatomy 0.000 description 2
- 230000009251 neurologic dysfunction Effects 0.000 description 2
- 208000015015 neurological dysfunction Diseases 0.000 description 2
- 230000004461 rapid eye movement Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 230000006403 short-term memory Effects 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 206010062501 Non-cardiac chest pain Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 101000999374 Rattus norvegicus Interferon-related developmental regulator 1 Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003838 injectable contraceptive agent Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000004370 retrospective diagnosis Methods 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000934 spermatocidal agent Substances 0.000 description 1
- 238000002660 stem cell treatment Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 229940079023 tysabri Drugs 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 238000007879 vasectomy Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Claims (4)
1. Glatirameracetat til anvendelse i et regimen på tre subkutane injektioner afen 40 mg dosis glatirameracetat hver syvende dag med mindst én dag imellem hver subkutan injektion til anvendelse i behandling af en patient der lider af en tilbagefaldsform af multipel sklerose eller som har gennemgået en første klinisk episode og er i højrisiko for at udvikle klinisk afgrænset multipel sklerose og hvor den farmaceutiske sammensætning yderligere omfatter mannitol.
2. Medikament omfattende glatirameracetat til anvendelse i behandling af en patient der lider af en tilbagefaldsform af multipel sklerose eller som har gennemgået en første klinisk episode og er i højrisiko for at udvikle klinisk afgrænset multipel sklerose, hvor medikamentet skal administreres i et regimen på tre subkutane injektioner af en 40 mg dosis glatirameracetat hver syvende dag med mindst én dag imellem hver subkutan injektion og hvor den farmaceutiske sammensætning yderligere omfatter mannitol.
3. Glatirameracetat til anvendelse ifølge krav 1, hvor tolerabiliteten af glatirameracetatbehandling i den humane patient er forøget ved at reducere frekvensen af en umiddelbar efter-injektions-reaktion eller en injektionsstedreaktion.
4. Medikament omfattende glatirameracetat til anvendelse ifølge krav 2, hvor tolerabiliteten af glatirameracetatbehandling i den humane patient er forøget ved at reducere frekvensen afen umiddelbar efter-injektions-reaktion eller en injektions-sted reaktion.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27468709P | 2009-08-20 | 2009-08-20 | |
US33761210P | 2010-02-11 | 2010-02-11 | |
EP13166080.5A EP2630962B1 (en) | 2009-08-20 | 2010-08-19 | Low Frequency Glatiramer Acetate Therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2949335T3 true DK2949335T3 (da) | 2017-07-31 |
Family
ID=43605835
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17157735.6T DK3199172T3 (da) | 2009-08-20 | 2010-08-19 | Doseringsregimen til multipel sklerose |
DK13166080.5T DK2630962T3 (da) | 2009-08-20 | 2010-08-19 | Lavfrekvent glatiramer-acetat-terapi |
DK10810282.3T DK2405749T3 (da) | 2009-08-20 | 2010-08-19 | Lavfrekvent glatiramer-acetat-terapi |
DK15171065.4T DK2949335T3 (da) | 2009-08-20 | 2010-08-19 | Lavfrekvent glatiramer-acetat-terapi |
DK201600003U DK201600003Y3 (da) | 2009-08-20 | 2016-01-06 | Lavfrekvent glatiramer-acetat-terapi |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17157735.6T DK3199172T3 (da) | 2009-08-20 | 2010-08-19 | Doseringsregimen til multipel sklerose |
DK13166080.5T DK2630962T3 (da) | 2009-08-20 | 2010-08-19 | Lavfrekvent glatiramer-acetat-terapi |
DK10810282.3T DK2405749T3 (da) | 2009-08-20 | 2010-08-19 | Lavfrekvent glatiramer-acetat-terapi |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK201600003U DK201600003Y3 (da) | 2009-08-20 | 2016-01-06 | Lavfrekvent glatiramer-acetat-terapi |
Country Status (34)
Country | Link |
---|---|
US (15) | US8399413B2 (da) |
EP (5) | EP2405749B1 (da) |
JP (3) | JP6038653B2 (da) |
KR (4) | KR20170123354A (da) |
CN (3) | CN102625657A (da) |
AR (2) | AR077896A1 (da) |
AT (1) | AT15421U1 (da) |
AU (1) | AU2010284666B2 (da) |
BR (1) | BR112012003730A2 (da) |
CA (2) | CA2760802C (da) |
CY (2) | CY1114537T1 (da) |
CZ (2) | CZ30474U1 (da) |
DE (1) | DE202010018377U1 (da) |
DK (5) | DK3199172T3 (da) |
EA (3) | EA032283B1 (da) |
ES (4) | ES2689711T3 (da) |
HK (4) | HK1165959A1 (da) |
HR (4) | HRP20130677T1 (da) |
HU (2) | HUE039335T2 (da) |
IL (3) | IL218106A0 (da) |
LT (3) | LT2949335T (da) |
ME (2) | ME02662B (da) |
MX (1) | MX2012002082A (da) |
NZ (1) | NZ598661A (da) |
PL (4) | PL2405749T3 (da) |
PT (4) | PT2405749E (da) |
RS (2) | RS52885B (da) |
SG (2) | SG10201405806SA (da) |
SI (4) | SI2949335T1 (da) |
SK (1) | SK501352015U1 (da) |
SM (1) | SMT201700057B (da) |
TW (3) | TWI643614B (da) |
UA (1) | UA103699C2 (da) |
WO (1) | WO2011022063A1 (da) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2527760T3 (es) * | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
US8077333B2 (en) * | 2002-09-09 | 2011-12-13 | Canon Kabushiki Kaisha | Printing control apparatus and printing control method |
LT2949335T (lt) * | 2009-08-20 | 2017-03-27 | Yeda Research & Development Company, Ltd. | Žemo dažnio glatiramero acetato terapija |
USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
EP2627669B1 (en) | 2010-10-11 | 2016-08-17 | Teva Pharmaceutical Industries Ltd. | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
WO2013055683A1 (en) | 2011-10-10 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
US9617596B2 (en) | 2012-10-10 | 2017-04-11 | Teva Pharmaceutical Industries, Ltd. | Biomarkers predictive for clinical response for glatiramer acetate |
EA201591251A1 (ru) * | 2013-01-04 | 2016-05-31 | Тева Фармасьютикал Индастриз Лтд. | Характеризация лекарственного продукта, родственного ацетату глатирамера |
UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
CN103641897B (zh) * | 2013-11-27 | 2017-01-04 | 深圳翰宇药业股份有限公司 | 一种合成醋酸格拉替雷的方法 |
US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
WO2015195605A1 (en) * | 2014-06-17 | 2015-12-23 | Teva Pharmaceutical Industries Ltd. | Transmucosal delivery of glatiramer acetate by oral patches |
CN104844697B (zh) * | 2014-09-26 | 2018-10-23 | 深圳翰宇药业股份有限公司 | 醋酸格拉替雷的制备方法 |
US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
CN107550853B (zh) * | 2016-06-30 | 2020-06-12 | 深圳翰宇药业股份有限公司 | 一种醋酸格拉替雷注射液的制备方法 |
BR112019003594A2 (pt) | 2016-08-31 | 2019-05-21 | Mapi Pharma Ltd | sistemas depot que compreendem acetato de glatirâmero |
WO2018106931A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
AU2018242998B2 (en) | 2017-03-26 | 2023-11-02 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
CA3067681A1 (en) * | 2017-06-26 | 2019-01-03 | Institut Pasteur | Treatments to eliminate hiv reservoirs and reduce viral load |
US20200306516A1 (en) | 2017-08-14 | 2020-10-01 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof |
KR102519053B1 (ko) | 2021-02-08 | 2023-04-06 | 건국대학교 산학협력단 | 염산가스의 농도 측정을 위한 수분 전처리 시스템 |
KR102519054B1 (ko) | 2021-03-12 | 2023-04-06 | 건국대학교 산학협력단 | 나피온 드라이어와 수분 전처리장치의 결합시스템 |
CA3221343A1 (en) * | 2021-10-11 | 2023-04-20 | Allitia DIBERNARDO | Methods of treating multiple sclerosis |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
DE3673317D1 (de) | 1985-10-11 | 1990-09-13 | Duphar Int Res | Automatische spritze. |
US5981485A (en) | 1997-07-14 | 1999-11-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
IL113812A (en) | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
IL119989A0 (en) | 1997-01-10 | 1997-04-15 | Yeda Res & Dev | Pharmaceutical compositions for oral treatment of multiple sclerosis |
US6214791B1 (en) | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
US6454746B1 (en) | 1997-06-04 | 2002-09-24 | Eli Lilly And Company | Medication delivery apparatus |
EP1105414A2 (en) | 1998-07-23 | 2001-06-13 | President And Fellows of Harvard College | Synthetic peptides and methods of use for autoimmune disease therapies |
ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
WO2000005250A1 (en) | 1998-07-23 | 2000-02-03 | Yeda Research And Development Co., Ltd | Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides |
US6514938B1 (en) | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
CA2343929C (en) | 1998-09-25 | 2013-01-29 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
WO2000020010A1 (en) | 1998-10-02 | 2000-04-13 | Yeda Research And Development Co., Ltd. | Alternate day administration of copolymer 1 for treating autoimmune diseases |
WO2000027417A1 (en) | 1998-11-12 | 2000-05-18 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd |
MXPA02002037A (es) | 1999-08-27 | 2002-10-31 | Genentech Inc | Dosificaciones para el tratamiento con anticuerpos anti-erb2. |
DK1248643T3 (da) | 2000-01-20 | 2005-11-07 | Yeda Res & Dev | Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celler behandlet dermed til neurobeskyttende terapi |
US7022663B2 (en) | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
DE60120648D1 (de) | 2000-02-18 | 2006-07-27 | Yeda Res & Dev | Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung |
US20020077278A1 (en) * | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
JP2003535118A (ja) | 2000-06-05 | 2003-11-25 | テバ ファーマシューティカル インダストリーズ リミティド | 中枢神経系障害の治療におけるグラチラマーアセテート(共重合体1)の使用 |
DE60116467T2 (de) | 2000-06-07 | 2006-11-02 | Yeda Research And Development Co., Ltd. | Verwendung des Copolymer-1 Peptids sowie von damit verwandten Peptiden und Polypeptiden und von damit behandelten T-Zellen zur Neuroprotektion gegen die Toxizität von Glutamat |
WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
MXPA04005433A (es) | 2001-12-04 | 2004-10-11 | Teva Pharma | Proceso para la medicion de la potencia de acetato de glatiramero. |
AU2003283152A1 (en) | 2002-11-13 | 2004-06-03 | Apotex Pharmachem Inc. | Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine |
AU2003275895B2 (en) | 2002-11-25 | 2009-02-05 | Tecpharma Licensing Ag | Auto-injector comprising a resettable releasing safety device |
US7274347B2 (en) | 2003-06-27 | 2007-09-25 | Texas Instruments Incorporated | Prevention of charge accumulation in micromirror devices through bias inversion |
EP1592384B1 (en) | 2003-01-21 | 2012-10-31 | Yeda Research And Development Co., Ltd. | Cop 1 for treatment of inflammatory bowel diseases |
CA2518079A1 (en) * | 2003-03-04 | 2004-10-28 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
PL1638589T3 (pl) * | 2003-05-14 | 2014-10-31 | Teva Pharmaceutical Industries Ltd | Terapia kombinowana obejmująca octan glatirameru i mitoksantron do leczenia stwardnienia rozsianego |
US20050170004A1 (en) | 2003-10-31 | 2005-08-04 | Vered Rosenberger | Nanoparticles for drug delivery |
HUP0303779A2 (en) * | 2003-11-20 | 2006-02-28 | Richter Gedeon Vegyeszet | Pharmaceutical compositions containing hyaluronan complex for the treatment of sclerosis multiplex |
AU2005218625A1 (en) | 2004-03-03 | 2005-09-15 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and riluzole |
EP1737297B1 (en) * | 2004-03-25 | 2012-12-19 | Janssen Pharmaceutica NV | Imidazole compounds |
US7655221B2 (en) | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
US20060194725A1 (en) | 2004-05-07 | 2006-08-31 | James Rasmussen | Methods of treating disease with random copolymers |
EP2508194A1 (en) | 2004-05-07 | 2012-10-10 | Ares Trading S.A. | Methods of treating disease with random copolymers |
ES2432369T3 (es) * | 2004-06-25 | 2013-12-03 | Id Biomedical Corporation Of Quebec | Composiciones y métodos para tratar trastornos neurológicos |
CA2579038A1 (en) * | 2004-09-02 | 2006-03-16 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis |
HUE028833T2 (en) * | 2004-09-09 | 2017-01-30 | Yeda Res & Dev | Polypeptide mixtures, compositions containing them, process for their preparation, and applications |
SI2361924T1 (sl) | 2004-09-09 | 2014-04-30 | Teva Pharmaceutical Industries Ltd. | Postopek za pripravo zmesi trifluoroacetil glatiramer acetata ob uporabi očiščene bromovodikove kisline |
EP1807467B1 (en) | 2004-10-29 | 2009-08-26 | Sandoz AG | Processes for preparing glatiramer |
UA93669C2 (ru) | 2005-02-02 | 2011-03-10 | Тева Фармасьютикл Индастриз, Лтд. | Способ приготовления полипептидной смеси c использованием гидрогенолиза |
US20100167983A1 (en) | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
SI1848415T1 (sl) | 2005-02-17 | 2013-08-30 | Teva Pharmaceutical Industries Ltd. | Kombinacijska terapija z glatiramer acetatom in razagilinom za zdravljenje muliple skleroze |
CA2606194A1 (en) | 2005-04-25 | 2006-11-02 | Yeda Research And Development Company | Markers associated with the therapeutic efficacy of glatiramer acetate |
US20070059798A1 (en) | 2005-09-09 | 2007-03-15 | Alexander Gad | Polypeptides useful for molecular weight determinations |
US20070161566A1 (en) | 2006-01-11 | 2007-07-12 | Teva Pharmaceutical Industries, Ltd. | Method of treating multiple sclerosis |
WO2007146331A1 (en) | 2006-06-12 | 2007-12-21 | Teva Pharmaceutical Industries, Ltd. | Tannate salt form of polypeptide mixtures, their preparation and use |
MX2008016335A (es) | 2006-06-30 | 2009-01-21 | Abbott Biotech Ltd | Dispositivo automatico de inyeccion. |
CA2656573A1 (en) | 2006-07-05 | 2008-01-10 | Momenta Pharmaceuticals, Inc. | Improved process for the preparation of copolymer-1 |
JP2010540634A (ja) * | 2007-10-01 | 2010-12-24 | ザ・ジョンズ・ホプキンス・ユニバーシティー | シクロホスファミドを用いて自己免疫神経疾患を処置する方法 |
KR20100102620A (ko) | 2007-11-28 | 2010-09-24 | 테바 파마슈티컬 인더스트리즈 리미티드 | 임상적 확진 다발성 경화증의 발병 지연 방법 |
PL2275086T3 (pl) | 2009-07-15 | 2012-09-28 | Teva Pharma | Formulacja octanu glatirameru o zredukowanej objętości oraz sposoby podawania |
US8920373B2 (en) | 2009-07-15 | 2014-12-30 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
LT2949335T (lt) | 2009-08-20 | 2017-03-27 | Yeda Research & Development Company, Ltd. | Žemo dažnio glatiramero acetato terapija |
US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
EP2627669B1 (en) | 2010-10-11 | 2016-08-17 | Teva Pharmaceutical Industries Ltd. | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
WO2013055683A1 (en) | 2011-10-10 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
US9617596B2 (en) | 2012-10-10 | 2017-04-11 | Teva Pharmaceutical Industries, Ltd. | Biomarkers predictive for clinical response for glatiramer acetate |
EA201591251A1 (ru) | 2013-01-04 | 2016-05-31 | Тева Фармасьютикал Индастриз Лтд. | Характеризация лекарственного продукта, родственного ацетату глатирамера |
US20140271630A1 (en) | 2013-03-12 | 2014-09-18 | Teva Pharmaceutical Industries, Ltd. | Rituximab induction therapy followed by glatiramer acetate therapy |
-
2010
- 2010-08-19 LT LTEP15171065.4T patent/LT2949335T/lt unknown
- 2010-08-19 US US12/806,684 patent/US8399413B2/en active Active
- 2010-08-19 WO PCT/US2010/002283 patent/WO2011022063A1/en active Application Filing
- 2010-08-19 HU HUE17157735A patent/HUE039335T2/hu unknown
- 2010-08-19 DK DK17157735.6T patent/DK3199172T3/da active
- 2010-08-19 DE DE202010018377.4U patent/DE202010018377U1/de not_active Ceased
- 2010-08-19 CA CA2760802A patent/CA2760802C/en active Active
- 2010-08-19 NZ NZ598661A patent/NZ598661A/xx unknown
- 2010-08-19 SG SG10201405806SA patent/SG10201405806SA/en unknown
- 2010-08-19 SI SI201031375A patent/SI2949335T1/sl unknown
- 2010-08-19 KR KR1020177031069A patent/KR20170123354A/ko not_active Application Discontinuation
- 2010-08-19 ES ES17157735.6T patent/ES2689711T3/es active Active
- 2010-08-19 EA EA201400394A patent/EA032283B1/ru unknown
- 2010-08-19 CN CN2010800369660A patent/CN102625657A/zh active Pending
- 2010-08-19 SI SI201030270T patent/SI2405749T1/sl unknown
- 2010-08-19 CZ CZ2016-33036U patent/CZ30474U1/cs not_active IP Right Cessation
- 2010-08-19 JP JP2012525530A patent/JP6038653B2/ja active Active
- 2010-08-19 SI SI201031719T patent/SI2630962T1/sl unknown
- 2010-08-19 CN CN201610878988.0A patent/CN107050423A/zh active Pending
- 2010-08-19 CA CA2876966A patent/CA2876966A1/en not_active Abandoned
- 2010-08-19 EP EP10810282.3A patent/EP2405749B1/en not_active Revoked
- 2010-08-19 AT ATGM50231/2015U patent/AT15421U1/de not_active IP Right Cessation
- 2010-08-19 RS RS20130293A patent/RS52885B/en unknown
- 2010-08-19 LT LTEP17157735.6T patent/LT3199172T/lt unknown
- 2010-08-19 CZ CZ2015-31885U patent/CZ29723U1/cs not_active IP Right Cessation
- 2010-08-19 PT PT108102823T patent/PT2405749E/pt unknown
- 2010-08-19 SI SI201031740T patent/SI3199172T1/sl unknown
- 2010-08-19 MX MX2012002082A patent/MX2012002082A/es active IP Right Grant
- 2010-08-19 ES ES15171065.4T patent/ES2612001T4/es active Active
- 2010-08-19 ME MEP-2017-17A patent/ME02662B/me unknown
- 2010-08-19 RS RS20170053A patent/RS55607B1/sr unknown
- 2010-08-19 BR BR112012003730-7A patent/BR112012003730A2/pt not_active Application Discontinuation
- 2010-08-19 KR KR1020127007115A patent/KR20120090044A/ko active Search and Examination
- 2010-08-19 PL PL10810282T patent/PL2405749T3/pl unknown
- 2010-08-19 EP EP15171065.4A patent/EP2949335B1/en not_active Revoked
- 2010-08-19 SG SG2012011425A patent/SG178495A1/en unknown
- 2010-08-19 CN CN201610104429.4A patent/CN105770855A/zh active Pending
- 2010-08-19 EP EP17157735.6A patent/EP3199172B1/en not_active Revoked
- 2010-08-19 PT PT131660805T patent/PT2630962T/pt unknown
- 2010-08-19 EA EA201270292A patent/EA019998B9/ru not_active IP Right Cessation
- 2010-08-19 EP EP18179172.4A patent/EP3409286B1/en active Active
- 2010-08-19 AU AU2010284666A patent/AU2010284666B2/en not_active Withdrawn - After Issue
- 2010-08-19 KR KR1020167006001A patent/KR20160038057A/ko not_active Application Discontinuation
- 2010-08-19 PL PL13166080T patent/PL2630962T3/pl unknown
- 2010-08-19 PL PL15171065T patent/PL2949335T3/pl unknown
- 2010-08-19 EP EP13166080.5A patent/EP2630962B1/en not_active Revoked
- 2010-08-19 PT PT151710654T patent/PT2949335T/pt unknown
- 2010-08-19 ME MEP-2013-81A patent/ME01536B/me unknown
- 2010-08-19 PL PL17157735T patent/PL3199172T3/pl unknown
- 2010-08-19 KR KR1020147012452A patent/KR20140061559A/ko not_active Application Discontinuation
- 2010-08-19 ES ES10810282T patent/ES2424692T3/es active Active
- 2010-08-19 ES ES13166080.5T patent/ES2688873T3/es active Active
- 2010-08-19 LT LTEP13166080.5T patent/LT2630962T/lt unknown
- 2010-08-19 EA EA201691347A patent/EA032287B1/ru unknown
- 2010-08-19 PT PT17157735T patent/PT3199172T/pt unknown
- 2010-08-19 DK DK13166080.5T patent/DK2630962T3/da active
- 2010-08-19 DK DK10810282.3T patent/DK2405749T3/da active
- 2010-08-19 DK DK15171065.4T patent/DK2949335T3/da active
- 2010-08-19 UA UAA201203259A patent/UA103699C2/ru unknown
- 2010-08-19 HU HUE15171065A patent/HUE031282T2/hu unknown
- 2010-08-20 TW TW103138861A patent/TWI643614B/zh not_active IP Right Cessation
- 2010-08-20 TW TW106100768A patent/TW201733575A/zh unknown
- 2010-08-20 AR ARP100103062A patent/AR077896A1/es not_active Application Discontinuation
- 2010-08-20 TW TW099128023A patent/TWI477273B/zh active
-
2011
- 2011-11-30 US US13/308,299 patent/US8232250B2/en not_active Expired - Fee Related
-
2012
- 2012-02-14 IL IL218106A patent/IL218106A0/en active IP Right Grant
- 2012-07-12 HK HK12106867.3A patent/HK1165959A1/xx not_active IP Right Cessation
-
2013
- 2013-02-19 US US13/770,677 patent/US8969302B2/en not_active Expired - Fee Related
- 2013-07-17 HR HRP20130677AT patent/HRP20130677T1/hr unknown
- 2013-07-22 CY CY20131100615T patent/CY1114537T1/el unknown
-
2014
- 2014-02-26 HK HK19100376.3A patent/HK1258008A1/zh unknown
- 2014-06-30 IL IL233468A patent/IL233468A0/en unknown
-
2015
- 2015-01-12 AR ARP150100073A patent/AR099078A2/es not_active Application Discontinuation
- 2015-02-24 US US14/630,326 patent/US20150164977A1/en not_active Abandoned
- 2015-03-30 US US14/673,257 patent/US9402874B2/en active Active
- 2015-05-13 JP JP2015098415A patent/JP6169644B2/ja active Active
- 2015-05-22 US US14/720,556 patent/US9155776B2/en not_active Expired - Fee Related
- 2015-12-18 SK SK50135-2015U patent/SK501352015U1/sk unknown
-
2016
- 2016-01-06 DK DK201600003U patent/DK201600003Y3/da not_active IP Right Cessation
- 2016-05-06 US US15/148,215 patent/US20160250251A1/en not_active Abandoned
- 2016-06-01 HK HK16106219.4A patent/HK1218250A1/zh not_active IP Right Cessation
- 2016-12-01 HK HK16113727A patent/HK1225310A1/zh unknown
- 2016-12-15 US US15/380,579 patent/US20170095523A1/en not_active Abandoned
-
2017
- 2017-01-13 HR HRP20170056TT patent/HRP20170056T2/hr unknown
- 2017-01-16 CY CY20171100052T patent/CY1118529T1/el unknown
- 2017-01-25 SM SM201700057T patent/SMT201700057B/it unknown
- 2017-02-22 JP JP2017031335A patent/JP2017132773A/ja not_active Withdrawn
- 2017-03-27 US US15/469,758 patent/US20170196803A1/en not_active Abandoned
- 2017-04-26 IL IL251943A patent/IL251943A0/en unknown
- 2017-07-05 US US15/642,201 patent/US20170296464A1/en not_active Abandoned
- 2017-11-13 US US15/811,495 patent/US20180064639A1/en not_active Abandoned
-
2018
- 2018-02-28 US US15/908,441 patent/US20180185274A1/en not_active Abandoned
- 2018-06-27 US US16/020,591 patent/US20180311149A1/en not_active Abandoned
- 2018-08-06 HR HRP20181253TT patent/HRP20181253T1/hr unknown
- 2018-08-06 HR HRP20181254TT patent/HRP20181254T1/hr unknown
- 2018-10-19 US US16/165,541 patent/US20190054013A1/en not_active Abandoned
-
2019
- 2019-02-11 US US16/272,786 patent/US20190175494A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2949335T3 (da) | Lavfrekvent glatiramer-acetat-terapi | |
AU2013203367B2 (en) | Low frequency glatiramer acetate therapy | |
AU2016100455A4 (en) | Low frequency glatiramer acetate therapy | |
AU2015101563A4 (en) | Low frequency glatiramer acetate therapy |